Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $9.25 and traded as high as $13.52. Bayer Aktiengesellschaft shares last traded at $13.41, with a volume of 2,856,719 shares traded.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 20th. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Three equities research analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the company’s stock. According to data from MarketBeat.com, Bayer Aktiengesellschaft has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Down 1.8%

The business has a fifty day moving average of $11.48 and a 200-day moving average of $9.25. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.